In a groundbreaking real-world study, researchers have demonstrated that a single dose of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) infections, significantly reduces hospitalizations due to bronchiolitis in infants. This antibody, already approved at the European level for protecting infants during their first exposure season to RSV, has been shown to halve hospital admissions among infants under six months of age. The study is the first to analyze the drug’s impact across different healthcare settings, bringing invaluable insight into its practical utility beyond controlled clinical trials.
RSV is a predominant cause of acute lower respiratory infections in young children worldwide, particularly causing bronchiolitis, which primarily affects infants under one year. Bronchiolitis manifests as inflammation of the small airways in the lungs, often leading to respiratory distress. The burden on healthcare systems is enormous during peak seasons, generally spanning from November through March in the Northern Hemisphere. Despite this significant impact, preventive options for RSV have historically been limited, mostly focusing on high-risk groups.
Nirsevimab represents a transformative approach in RSV prophylaxis. Unlike traditional immunization, this monoclonal antibody provides passive immunity by delivering specific, potent antibodies that neutralize RSV upon exposure. Due to its extended half-life, a single dose offers protection that spans the critical initial months of life, particularly guarding infants during their highest vulnerability period. The antibody has shown promising efficacy in clinical settings, but its effect on real-world population health and differing national policies was previously uncharted.
.adsslot_auOzwD3L5j{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_auOzwD3L5j{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_auOzwD3L5j{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
The multinational study, published in The Lancet Regional Health – Europe on June 3, 2025, was a collaborative effort involving leading institutions across Europe, including the Università Cattolica del Sacro Cuore in Rome, the Universitat Politècnica de Catalunya in Spain, the Leicester Royal Infirmary, and the University of Edinburgh. Dr. Danilo Buonsenso, a paediatrician and researcher coordinating the study, emphasized the novelty of comparing real-world outcomes between countries that have adopted nirsevimab use and those yet to implement it.
Data was gathered retrospectively from 68 Catalan hospitals, where nirsevimab was introduced during the 2023-2024 season, alongside 5 hospitals in the United Kingdom and Italy, where the antibody has not yet been systematically deployed. The results were striking: among infants younger than six months in Catalonia, hospitalization rates for bronchiolitis dropped by nearly 50% compared to averages of preceding seasons. Emergency department attendances for bronchiolitis in this age group also showed a marked decline.
In contrast, comparable healthcare centers in the UK and Italy, where nirsevimab had not been administered, recorded no significant decrease in bronchiolitis hospitalizations or emergency visits. This divergence provides compelling evidence that the antibody’s protective benefits translated effectively outside clinical trials into routine clinical practice in Catalonia, where the preventive strategy was systematically implemented.
The protective effect of nirsevimab was most pronounced in infants under six months. For children aged between six months and two years, the reduction in hospitalization was less marked, suggesting that the antibody’s primary efficacy window aligns with the period of highest RSV susceptibility. This finding underscores the importance of early administration, ideally before or at the onset of the first potential exposure season, to maximally leverage passive immunity.
Bronchiolitis is mainly triggered by RSV in about 75% of cases, but other respiratory viruses such as human metapneumovirus, rhinoviruses, coronaviruses, adenoviruses, influenza, and parainfluenza can also initiate or exacerbate the condition. The spectrum of viral pathogens and transmission modes — primarily via contact with infected secretions—complicates preventive strategies that are virus-specific. Hence, targeting RSV effectively with nirsevimab could markedly reduce the overall bronchiolitis disease burden, even in the presence of other viral agents.
This study’s real-world evidence is paramount in guiding public health policies. It not only confirms the safety and efficacy profile of nirsevimab established in clinical trials but also elucidates its tangible impact within heterogeneous healthcare systems and varying epidemiological contexts. Such data are critical for healthcare authorities evaluating the integration of new preventive modalities into national immunization schedules.
Moreover, the study highlights the urgent need for concerted international research efforts to expand sample sizes and geographic representation. Evaluating cost-effectiveness and resource allocation strategies will be essential to ensure sustainable broad access to nirsevimab, particularly in resource-limited settings or countries with varying health infrastructure capabilities.
By comparing different European regions with distinct health policies and RSV prevention strategies, this analysis sheds light on how policy decisions translate into meaningful clinical outcomes. It sets a precedent for real-world effectiveness studies of innovative biotherapeutics, emphasizing the interplay between scientific innovation, clinical implementation, and population health impact.
In conclusion, the deployment of nirsevimab signifies a major advancement in protecting vulnerable infants from RSV-related bronchiolitis. The substantial decrease in hospitalizations and emergency visits observed in Catalonia serves as a powerful argument for broader adoption of this prophylactic approach. Future studies will not only refine understanding of age-specific efficacy but also explore the long-term benefits of reducing early-life respiratory morbidity.
This pioneering research offers hope for lowering the global health burden of RSV, which remains a major cause of infant morbidity and mortality. With the growing adoption of long-acting monoclonal antibodies like nirsevimab, the prospect of effectively controlling seasonal respiratory infections among the youngest and most vulnerable patients is closer than ever before.
Subject of Research: Real-world impact of nirsevimab immunisation on hospitalizations and emergency attendances for bronchiolitis in infants.
Article Title: Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis.
News Publication Date: 3-Jun-2025
References: Published in The Lancet Regional Health – Europe.
Keywords: Human health, Respiratory syncytial virus, Bronchiolitis, Infants, Monoclonal antibody, Nirsevimab, Real-world study, Pediatric infectious diseases, RSV prophylaxis, Hospitalization reduction.
Tags: bronchiolitis in infants under six monthshealthcare burden of RSVimpact of monoclonal antibodies in pediatric careinfant respiratory health interventionsmonoclonal antibody therapy for RSVnirsevimab effectiveness in bronchiolitis preventionpassive immunity in newbornsreal-world studies on drug efficacyreducing infant hospitalizations for respiratory infectionsrespiratory syncytial virus treatment innovationsRSV prophylaxis advancementsseasonal respiratory infection patterns
